DK2588130T3 - Cns delivery of therapeutic agents - Google Patents

Info

Publication number

DK2588130T3

DK2588130T3 DK11799035.8T DK11799035T DK2588130T3 DK 2588130 T3 DK2588130 T3 DK 2588130T3 DK 11799035 T DK11799035 T DK 11799035T DK 2588130 T3 DK2588130 T3 DK 2588130T3

Authority

DK

Denmark

Prior art keywords

brain

dose

tissues

enzyme

administration

Prior art date

2010-06-25

Links

• Espacenet
• Global Dossier
• Discuss

• 238000012384 transportation and delivery Methods 0.000 title description 78
• 239000003814 drug Substances 0.000 title description 47
• 229940124597 therapeutic agent Drugs 0.000 title description 42
• 210000004556 brain Anatomy 0.000 claims description 275
• 238000007913 intrathecal administration Methods 0.000 claims description 260
• 102000004190 Enzymes Human genes 0.000 claims description 256
• 108090000790 Enzymes Proteins 0.000 claims description 256
• 239000000203 mixture Substances 0.000 claims description 149
• 102100029199 Iduronate 2-sulfatase Human genes 0.000 claims description 119
• 101710096421 Iduronate 2-sulfatase Proteins 0.000 claims description 113
• 238000011282 treatment Methods 0.000 claims description 111
• 230000000694 effects Effects 0.000 claims description 92
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 86
• 210000003169 central nervous system Anatomy 0.000 claims description 76
• 230000002132 lysosomal effect Effects 0.000 claims description 76
• 208000015439 Lysosomal storage disease Diseases 0.000 claims description 67
• 201000010099 disease Diseases 0.000 claims description 66
• 238000000034 method Methods 0.000 claims description 56
• 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 46
• 208000028226 Krabbe disease Diseases 0.000 claims description 46
• 230000001225 therapeutic effect Effects 0.000 claims description 39
• 239000008194 pharmaceutical composition Substances 0.000 claims description 38
• 108010089932 heparan sulfate sulfatase Proteins 0.000 claims description 33
• 102100022146 Arylsulfatase A Human genes 0.000 claims description 32
• 108010036867 Cerebroside-Sulfatase Proteins 0.000 claims description 32
• 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims description 22
• 229910019142 PO4 Inorganic materials 0.000 claims description 21
• 230000003247 decreasing effect Effects 0.000 claims description 21
• 239000010452 phosphate Substances 0.000 claims description 20
• 239000000872 buffer Substances 0.000 claims description 19
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 19
• 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 claims description 17
• 201000002273 mucopolysaccharidosis II Diseases 0.000 claims description 16
• 208000025816 Sanfilippo syndrome type A Diseases 0.000 claims description 11
• 208000036710 mucopolysaccharidosis type 3A Diseases 0.000 claims description 11
• 208000012226 mucopolysaccharidosis type IIIA Diseases 0.000 claims description 11
• 239000003795 chemical substances by application Substances 0.000 claims description 9
• 239000006172 buffering agent Substances 0.000 claims description 3
• 239000012756 surface treatment agent Substances 0.000 claims 1
• 210000001519 tissue Anatomy 0.000 description 320
• 229940088598 enzyme Drugs 0.000 description 250
• 241001465754 Metazoa Species 0.000 description 170
• 239000007924 injection Substances 0.000 description 121
• 238000002347 injection Methods 0.000 description 121
• 210000002966 serum Anatomy 0.000 description 101
• 239000008280 blood Substances 0.000 description 97
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 91
• 108090000623 proteins and genes Proteins 0.000 description 90
• 238000009472 formulation Methods 0.000 description 88
• 210000004027 cell Anatomy 0.000 description 87
• 102000004169 proteins and genes Human genes 0.000 description 85
• 241000699670 Mus sp. Species 0.000 description 84
• 210000004369 blood Anatomy 0.000 description 82
• 238000001990 intravenous administration Methods 0.000 description 80
• 210000004185 liver Anatomy 0.000 description 76
• 210000000278 spinal cord Anatomy 0.000 description 71
• 238000010186 staining Methods 0.000 description 64
• 210000004885 white matter Anatomy 0.000 description 58
• 210000003734 kidney Anatomy 0.000 description 54
• 210000002569 neuron Anatomy 0.000 description 53
• 210000004720 cerebrum Anatomy 0.000 description 52
• 230000009467 reduction Effects 0.000 description 45
• 210000003743 erythrocyte Anatomy 0.000 description 43
• 238000004458 analytical method Methods 0.000 description 42
• 108010009254 Lysosomal-Associated Membrane Protein 1 Proteins 0.000 description 41
• 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 41
• 241000699666 Mus <mouse, genus> Species 0.000 description 39
• 238000013222 sprague-dawley male rat Methods 0.000 description 39
• 239000000463 material Substances 0.000 description 38
• 210000002990 parathyroid gland Anatomy 0.000 description 38
• 210000001685 thyroid gland Anatomy 0.000 description 38
• HHJTWTPUPVQKNA-PIIMIWFASA-N psychosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O HHJTWTPUPVQKNA-PIIMIWFASA-N 0.000 description 36
• 230000002829 reductive effect Effects 0.000 description 36
• 208000024891 symptom Diseases 0.000 description 36
• HHJTWTPUPVQKNA-UHFFFAOYSA-N psychosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)COC1OC(CO)C(O)C(O)C1O HHJTWTPUPVQKNA-UHFFFAOYSA-N 0.000 description 34
• 238000003860 storage Methods 0.000 description 34
• 241000700159 Rattus Species 0.000 description 33
• 101150022753 galc gene Proteins 0.000 description 33
• 238000012744 immunostaining Methods 0.000 description 33
• 210000001638 cerebellum Anatomy 0.000 description 31
• 238000009826 distribution Methods 0.000 description 29
• 230000004083 survival effect Effects 0.000 description 29
• 241000282693 Cercopithecidae Species 0.000 description 27
• 241000282414 Homo sapiens Species 0.000 description 27
• 210000005013 brain tissue Anatomy 0.000 description 27
• 238000013213 extrapolation Methods 0.000 description 27
• 230000001965 increasing effect Effects 0.000 description 27
• 239000010410 layer Substances 0.000 description 27
• 239000000243 solution Substances 0.000 description 26
• 238000003364 immunohistochemistry Methods 0.000 description 25
• 210000004072 lung Anatomy 0.000 description 25
• 230000001413 cellular effect Effects 0.000 description 24
• 230000002093 peripheral effect Effects 0.000 description 24
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
• 210000004884 grey matter Anatomy 0.000 description 23
• 238000007912 intraperitoneal administration Methods 0.000 description 23
• 210000000952 spleen Anatomy 0.000 description 23
• 230000002739 subcortical effect Effects 0.000 description 23
• 238000012360 testing method Methods 0.000 description 23
• 210000000601 blood cell Anatomy 0.000 description 22
• 230000002490 cerebral effect Effects 0.000 description 22
• 238000011887 Necropsy Methods 0.000 description 21
• 230000037396 body weight Effects 0.000 description 21
• 210000003712 lysosome Anatomy 0.000 description 21
• 230000001868 lysosomic effect Effects 0.000 description 21
• 210000002418 meninge Anatomy 0.000 description 21
• 239000012530 fluid Substances 0.000 description 20
• 230000006870 function Effects 0.000 description 20
• 238000005259 measurement Methods 0.000 description 20
• 230000003442 weekly effect Effects 0.000 description 20
• 241000282567 Macaca fascicularis Species 0.000 description 19
• 150000001413 amino acids Chemical group 0.000 description 18
• 210000003710 cerebral cortex Anatomy 0.000 description 18
• 210000002216 heart Anatomy 0.000 description 18
• 235000021317 phosphate Nutrition 0.000 description 18
• 210000001103 thalamus Anatomy 0.000 description 18
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
• 229920002683 Glycosaminoglycan Polymers 0.000 description 17
• 210000000133 brain stem Anatomy 0.000 description 17
• 230000002950 deficient Effects 0.000 description 17
• 210000004498 neuroglial cell Anatomy 0.000 description 17
• 238000001356 surgical procedure Methods 0.000 description 17
• 238000009825 accumulation Methods 0.000 description 16
• 230000000366 juvenile effect Effects 0.000 description 16
• 239000011780 sodium chloride Substances 0.000 description 16
• 210000004100 adrenal gland Anatomy 0.000 description 15
• 230000007812 deficiency Effects 0.000 description 15
• 238000002641 enzyme replacement therapy Methods 0.000 description 15
• 210000000449 purkinje cell Anatomy 0.000 description 15
• 238000011084 recovery Methods 0.000 description 15
• 210000002784 stomach Anatomy 0.000 description 15
• 230000008901 benefit Effects 0.000 description 14
• 208000035475 disorder Diseases 0.000 description 14
• 210000004940 nucleus Anatomy 0.000 description 14
• 238000002560 therapeutic procedure Methods 0.000 description 14
• 229940024606 amino acid Drugs 0.000 description 13
• 230000007423 decrease Effects 0.000 description 13
• 239000003018 immunosuppressive agent Substances 0.000 description 13
• 230000006872 improvement Effects 0.000 description 13
• 208000008955 Mucolipidoses Diseases 0.000 description 12
• 230000000875 corresponding effect Effects 0.000 description 12
• 238000010790 dilution Methods 0.000 description 12
• 239000012895 dilution Substances 0.000 description 12
• 108090000765 processed proteins & peptides Proteins 0.000 description 12
• 239000011734 sodium Substances 0.000 description 12
• 230000002477 vacuolizing effect Effects 0.000 description 12
• 102100028496 Galactocerebrosidase Human genes 0.000 description 11
• 108010042681 Galactosylceramidase Proteins 0.000 description 11
• 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 11
• 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 11
• 210000001159 caudate nucleus Anatomy 0.000 description 11
• 239000007788 liquid Substances 0.000 description 11
• 210000004705 lumbosacral region Anatomy 0.000 description 11
• 150000003839 salts Chemical class 0.000 description 11
• 239000000523 sample Substances 0.000 description 11
• 210000003932 urinary bladder Anatomy 0.000 description 11
• 208000002678 Mucopolysaccharidoses Diseases 0.000 description 10
• 238000013103 analytical ultracentrifugation Methods 0.000 description 10
• 210000003703 cisterna magna Anatomy 0.000 description 10
• 208000010877 cognitive disease Diseases 0.000 description 10
• 230000008030 elimination Effects 0.000 description 10
• 238000003379 elimination reaction Methods 0.000 description 10
• 230000002255 enzymatic effect Effects 0.000 description 10
• 210000003736 gastrointestinal content Anatomy 0.000 description 10
• 229960003444 immunosuppressant agent Drugs 0.000 description 10
• 206010028093 mucopolysaccharidosis Diseases 0.000 description 10
• 210000003205 muscle Anatomy 0.000 description 10
• 102000004196 processed proteins & peptides Human genes 0.000 description 10
• 210000003497 sciatic nerve Anatomy 0.000 description 10
• 210000000813 small intestine Anatomy 0.000 description 10
• 239000001488 sodium phosphate Substances 0.000 description 10
• 229910000162 sodium phosphate Inorganic materials 0.000 description 10
• 235000011008 sodium phosphates Nutrition 0.000 description 10
• 239000000126 substance Substances 0.000 description 10
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 10
• 102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 description 9
• 101710145225 Cation-independent mannose-6-phosphate receptor Proteins 0.000 description 9
• NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 9
• 230000008499 blood brain barrier function Effects 0.000 description 9
• 210000001218 blood-brain barrier Anatomy 0.000 description 9
• 230000004700 cellular uptake Effects 0.000 description 9
• 210000000877 corpus callosum Anatomy 0.000 description 9
• 230000001054 cortical effect Effects 0.000 description 9
• 210000001320 hippocampus Anatomy 0.000 description 9
• 238000011532 immunohistochemical staining Methods 0.000 description 9
• 210000004248 oligodendroglia Anatomy 0.000 description 9
• 210000000056 organ Anatomy 0.000 description 9
• 239000008188 pellet Substances 0.000 description 9
• 229920001184 polypeptide Polymers 0.000 description 9
• 239000006228 supernatant Substances 0.000 description 9
• 230000008685 targeting Effects 0.000 description 9
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 9
• 206010053567 Coagulopathies Diseases 0.000 description 8
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
• 230000004071 biological effect Effects 0.000 description 8
• 239000004067 bulking agent Substances 0.000 description 8
• 230000015556 catabolic process Effects 0.000 description 8
• 230000035602 clotting Effects 0.000 description 8
• 235000005911 diet Nutrition 0.000 description 8
• 230000005021 gait Effects 0.000 description 8
• 230000028993 immune response Effects 0.000 description 8
• 238000001802 infusion Methods 0.000 description 8
• 210000002429 large intestine Anatomy 0.000 description 8
• 239000003550 marker Substances 0.000 description 8
• 238000001000 micrograph Methods 0.000 description 8
• 239000002052 molecular layer Substances 0.000 description 8
• 150000007523 nucleic acids Chemical class 0.000 description 8
• 102000005962 receptors Human genes 0.000 description 8
• 108020003175 receptors Proteins 0.000 description 8
• 239000003381 stabilizer Substances 0.000 description 8
• 239000002202 Polyethylene glycol Substances 0.000 description 7
• 208000025820 Sanfilippo syndrome type B Diseases 0.000 description 7
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
• 229930006000 Sucrose Natural products 0.000 description 7
• 230000002411 adverse Effects 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 210000000988 bone and bone Anatomy 0.000 description 7
• 238000006731 degradation reaction Methods 0.000 description 7
• 230000037213 diet Effects 0.000 description 7
• 238000009792 diffusion process Methods 0.000 description 7
• 238000012377 drug delivery Methods 0.000 description 7
• 210000003494 hepatocyte Anatomy 0.000 description 7
• 230000001861 immunosuppressant effect Effects 0.000 description 7
• 230000001976 improved effect Effects 0.000 description 7
• 238000000185 intracerebroventricular administration Methods 0.000 description 7
• 230000007246 mechanism Effects 0.000 description 7
• 239000012528 membrane Substances 0.000 description 7
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 7
• 208000036709 mucopolysaccharidosis type 3B Diseases 0.000 description 7
• 208000012227 mucopolysaccharidosis type IIIB Diseases 0.000 description 7
• 239000012071 phase Substances 0.000 description 7
• 229920001223 polyethylene glycol Polymers 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• 230000000750 progressive effect Effects 0.000 description 7
• 210000002637 putamen Anatomy 0.000 description 7
• -1 sodium octyl glycoside Chemical class 0.000 description 7
• 239000000758 substrate Substances 0.000 description 7
• 239000005720 sucrose Substances 0.000 description 7
• 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 6
• 208000028698 Cognitive impairment Diseases 0.000 description 6
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
• 208000001905 GM2 Gangliosidoses Diseases 0.000 description 6
• 201000008905 GM2 gangliosidosis Diseases 0.000 description 6
• 206010053185 Glycogen storage disease type II Diseases 0.000 description 6
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
• 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 description 6
• 206010072927 Mucolipidosis type I Diseases 0.000 description 6
• 206010028095 Mucopolysaccharidosis IV Diseases 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 108010005774 beta-Galactosidase Proteins 0.000 description 6
• 102000005936 beta-Galactosidase Human genes 0.000 description 6
• 239000003085 diluting agent Substances 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 210000001035 gastrointestinal tract Anatomy 0.000 description 6
• 230000036541 health Effects 0.000 description 6
• 108010072166 idursulfase Proteins 0.000 description 6
• 229960002396 idursulfase Drugs 0.000 description 6
• 210000002570 interstitial cell Anatomy 0.000 description 6
• 230000000670 limiting effect Effects 0.000 description 6
• 238000004519 manufacturing process Methods 0.000 description 6
• 230000007659 motor function Effects 0.000 description 6
• 208000010978 mucopolysaccharidosis type 4 Diseases 0.000 description 6
• 230000001575 pathological effect Effects 0.000 description 6
• 230000002688 persistence Effects 0.000 description 6
• 238000002203 pretreatment Methods 0.000 description 6
• 238000004062 sedimentation Methods 0.000 description 6
• 239000004094 surface-active agent Substances 0.000 description 6
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 5
• 206010012559 Developmental delay Diseases 0.000 description 5
• 241001076388 Fimbria Species 0.000 description 5
• 208000015872 Gaucher disease Diseases 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 208000028782 Hereditary disease Diseases 0.000 description 5
• 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 5
• 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 5
• 208000024556 Mendelian disease Diseases 0.000 description 5
• 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 5
• 241000288906 Primates Species 0.000 description 5
• 210000001744 T-lymphocyte Anatomy 0.000 description 5
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 5
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 5
• 238000013459 approach Methods 0.000 description 5
• 239000000090 biomarker Substances 0.000 description 5
• 210000001185 bone marrow Anatomy 0.000 description 5
• 159000000007 calcium salts Chemical class 0.000 description 5
• 210000003591 cerebellar nuclei Anatomy 0.000 description 5
• 230000003111 delayed effect Effects 0.000 description 5
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 210000003979 eosinophil Anatomy 0.000 description 5
• 238000004108 freeze drying Methods 0.000 description 5
• 108020001507 fusion proteins Proteins 0.000 description 5
• 102000037865 fusion proteins Human genes 0.000 description 5
• 210000003016 hypothalamus Anatomy 0.000 description 5
• 230000006058 immune tolerance Effects 0.000 description 5
• 238000003780 insertion Methods 0.000 description 5
• 230000037431 insertion Effects 0.000 description 5
• 230000004807 localization Effects 0.000 description 5
• 229920002521 macromolecule Polymers 0.000 description 5
• 210000001259 mesencephalon Anatomy 0.000 description 5
• 230000002503 metabolic effect Effects 0.000 description 5
• DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 description 5
• 229920001542 oligosaccharide Polymers 0.000 description 5
• 150000002482 oligosaccharides Chemical class 0.000 description 5
• 210000003463 organelle Anatomy 0.000 description 5
• 210000004786 perivascular cell Anatomy 0.000 description 5
• 239000002953 phosphate buffered saline Substances 0.000 description 5
• 210000003446 pia mater Anatomy 0.000 description 5
• 238000001556 precipitation Methods 0.000 description 5
• 210000003491 skin Anatomy 0.000 description 5
• 238000004611 spectroscopical analysis Methods 0.000 description 5
• 235000000346 sugar Nutrition 0.000 description 5
• 230000002459 sustained effect Effects 0.000 description 5
• 230000001839 systemic circulation Effects 0.000 description 5
• 229940073455 tetraethylammonium hydroxide Drugs 0.000 description 5
• LRGJRHZIDJQFCL-UHFFFAOYSA-M tetraethylazanium;hydroxide Chemical compound [OH-].CC[N+](CC)(CC)CC LRGJRHZIDJQFCL-UHFFFAOYSA-M 0.000 description 5
• 210000003934 vacuole Anatomy 0.000 description 5
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
• 206010067484 Adverse reaction Diseases 0.000 description 4
• 241000282472 Canis lupus familiaris Species 0.000 description 4
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
• 208000001948 Farber Lipogranulomatosis Diseases 0.000 description 4
• 208000033149 Farber disease Diseases 0.000 description 4
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
• 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 4
• 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• 229920002971 Heparan sulfate Polymers 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
• 102000038460 IGF Type 2 Receptor Human genes 0.000 description 4
• 108010031792 IGF Type 2 Receptor Proteins 0.000 description 4
• 229930195725 Mannitol Natural products 0.000 description 4
• 206010056893 Mucopolysaccharidosis VII Diseases 0.000 description 4
• 208000012902 Nervous system disease Diseases 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 239000013543 active substance Substances 0.000 description 4
• 210000000577 adipose tissue Anatomy 0.000 description 4
• 230000006838 adverse reaction Effects 0.000 description 4
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 4
• 108010009380 alpha-N-acetyl-D-glucosaminidase Proteins 0.000 description 4
• 210000000576 arachnoid Anatomy 0.000 description 4
• 230000003376 axonal effect Effects 0.000 description 4
• 210000004958 brain cell Anatomy 0.000 description 4
• 238000004364 calculation method Methods 0.000 description 4
• 210000003198 cerebellar cortex Anatomy 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 230000006735 deficit Effects 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 210000002451 diencephalon Anatomy 0.000 description 4
• 230000007613 environmental effect Effects 0.000 description 4
• 230000029142 excretion Effects 0.000 description 4
• 210000001508 eye Anatomy 0.000 description 4
• 229930182830 galactose Natural products 0.000 description 4
• 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 4
• 201000004502 glycogen storage disease II Diseases 0.000 description 4
• 201000008977 glycoproteinosis Diseases 0.000 description 4
• 230000006057 immunotolerant effect Effects 0.000 description 4
• 210000002425 internal capsule Anatomy 0.000 description 4
• 239000007928 intraperitoneal injection Substances 0.000 description 4
• 229910052740 iodine Inorganic materials 0.000 description 4
• 239000011630 iodine Substances 0.000 description 4
• 210000003292 kidney cell Anatomy 0.000 description 4
• 210000005229 liver cell Anatomy 0.000 description 4
• 230000007774 longterm Effects 0.000 description 4
• 239000000594 mannitol Substances 0.000 description 4
• 235000010355 mannitol Nutrition 0.000 description 4
• 230000002025 microglial effect Effects 0.000 description 4
• 238000002156 mixing Methods 0.000 description 4
• 238000013425 morphometry Methods 0.000 description 4
• 238000010172 mouse model Methods 0.000 description 4
• 201000007769 mucolipidosis Diseases 0.000 description 4
• 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 description 4
• 230000001537 neural effect Effects 0.000 description 4
• 108020004707 nucleic acids Proteins 0.000 description 4
• 102000039446 nucleic acids Human genes 0.000 description 4
• 230000007170 pathology Effects 0.000 description 4
• 239000008177 pharmaceutical agent Substances 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 230000000717 retained effect Effects 0.000 description 4
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
• 230000000392 somatic effect Effects 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 238000007910 systemic administration Methods 0.000 description 4
• 230000009885 systemic effect Effects 0.000 description 4
• 210000000689 upper leg Anatomy 0.000 description 4
• WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 3
• 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 description 3
• 208000031277 Amaurotic familial idiocy Diseases 0.000 description 3
• 206010002091 Anaesthesia Diseases 0.000 description 3
• 206010003694 Atrophy Diseases 0.000 description 3
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
• 108010036949 Cyclosporine Proteins 0.000 description 3
• 206010011878 Deafness Diseases 0.000 description 3
• 208000016192 Demyelinating disease Diseases 0.000 description 3
• 206010012305 Demyelination Diseases 0.000 description 3
• 241000283070 Equus zebra Species 0.000 description 3
• 208000024720 Fabry Disease Diseases 0.000 description 3
• 101000901140 Homo sapiens Arylsulfatase A Proteins 0.000 description 3
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• 208000033868 Lysosomal disease Diseases 0.000 description 3
• 102000006386 Myelin Proteins Human genes 0.000 description 3
• 108010083674 Myelin Proteins Proteins 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• 208000027418 Wounds and injury Diseases 0.000 description 3
• 230000002776 aggregation Effects 0.000 description 3
• 238000004220 aggregation Methods 0.000 description 3
• 230000037005 anaesthesia Effects 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 230000037444 atrophy Effects 0.000 description 3
• 239000008228 bacteriostatic water for injection Substances 0.000 description 3
• 210000004227 basal ganglia Anatomy 0.000 description 3
• 210000004204 blood vessel Anatomy 0.000 description 3
• RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 3
• 229960001736 buprenorphine Drugs 0.000 description 3
• 210000004289 cerebral ventricle Anatomy 0.000 description 3
• 238000012512 characterization method Methods 0.000 description 3
• 229960001265 ciclosporin Drugs 0.000 description 3
• 230000003750 conditioning effect Effects 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• 230000001434 glomerular Effects 0.000 description 3
• 210000003904 glomerular cell Anatomy 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 210000003128 head Anatomy 0.000 description 3
• 208000016354 hearing loss disease Diseases 0.000 description 3
• 229940125721 immunosuppressive agent Drugs 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 238000007917 intracranial administration Methods 0.000 description 3
• 229960002725 isoflurane Drugs 0.000 description 3
• 239000000644 isotonic solution Substances 0.000 description 3
• 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 3
• 238000002372 labelling Methods 0.000 description 3
• 210000005228 liver tissue Anatomy 0.000 description 3
• 210000001165 lymph node Anatomy 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 238000002844 melting Methods 0.000 description 3
• 230000008018 melting Effects 0.000 description 3
• 230000004060 metabolic process Effects 0.000 description 3
• 230000035772 mutation Effects 0.000 description 3
• 210000005012 myelin Anatomy 0.000 description 3
• 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 3
• 239000012188 paraffin wax Substances 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 210000000578 peripheral nerve Anatomy 0.000 description 3
• 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 3
• 210000002381 plasma Anatomy 0.000 description 3
• 229920001983 poloxamer Polymers 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 210000003625 skull Anatomy 0.000 description 3
• WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 210000000115 thoracic cavity Anatomy 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 238000002054 transplantation Methods 0.000 description 3
• 230000002861 ventricular Effects 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 2
• CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
• DIHXSRXTECMMJY-MURFETPASA-N 2-[dimethyl-[(9z,12z)-octadeca-9,12-dienyl]azaniumyl]acetate Chemical group CCCCC\C=C/C\C=C/CCCCCCCC[N+](C)(C)CC([O-])=O DIHXSRXTECMMJY-MURFETPASA-N 0.000 description 2
• WTWSDDKGKIGSJE-UHFFFAOYSA-N 5-(4-aminophenyl)cyclohexa-2,4-diene-1,1,2-triamine;tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.C1C(N)(N)C(N)=CC=C1C1=CC=C(N)C=C1 WTWSDDKGKIGSJE-UHFFFAOYSA-N 0.000 description 2
• 102100027165 Alpha-2-macroglobulin receptor-associated protein Human genes 0.000 description 2
• 101710126837 Alpha-2-macroglobulin receptor-associated protein Proteins 0.000 description 2
• 102100035028 Alpha-L-iduronidase Human genes 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 208000029602 Alpha-N-acetylgalactosaminidase deficiency Diseases 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 206010068220 Aspartylglucosaminuria Diseases 0.000 description 2
• 201000004569 Blindness Diseases 0.000 description 2
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
• YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
• 241000282465 Canis Species 0.000 description 2
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
• 206010010904 Convulsion Diseases 0.000 description 2
• 229930105110 Cyclosporin A Natural products 0.000 description 2
• 206010011777 Cystinosis Diseases 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• 208000011518 Danon disease Diseases 0.000 description 2
• 101710190709 Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 2
• 206010015548 Euthanasia Diseases 0.000 description 2
• 206010015719 Exsanguination Diseases 0.000 description 2
• 108010049003 Fibrinogen Proteins 0.000 description 2
• 102000008946 Fibrinogen Human genes 0.000 description 2
• 201000008892 GM1 Gangliosidosis Diseases 0.000 description 2
• 208000017462 Galactosialidosis Diseases 0.000 description 2
• 208000001500 Glycogen Storage Disease Type IIb Diseases 0.000 description 2
• 208000035148 Glycogen storage disease due to LAMP-2 deficiency Diseases 0.000 description 2
• 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 2
• 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 description 2
• 101100121090 Homo sapiens GALC gene Proteins 0.000 description 2
• 108700037017 Hyaluronidase Deficiency Proteins 0.000 description 2
• 208000005503 Hyaluronidase deficiency Diseases 0.000 description 2
• 102000004157 Hydrolases Human genes 0.000 description 2
• 108090000604 Hydrolases Proteins 0.000 description 2
• 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 208000026350 Inborn Genetic disease Diseases 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• 208000027933 Mannosidase Deficiency disease Diseases 0.000 description 2
• 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 2
• 208000036626 Mental retardation Diseases 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• 206010072929 Mucolipidosis type III Diseases 0.000 description 2
• 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 2
• 208000028781 Mucopolysaccharidosis type 1 Diseases 0.000 description 2
• 208000025797 Mucopolysaccharidosis type 4A Diseases 0.000 description 2
• 208000025923 Mucopolysaccharidosis type 4B Diseases 0.000 description 2
• 208000025915 Mucopolysaccharidosis type 6 Diseases 0.000 description 2
• 208000000149 Multiple Sulfatase Deficiency Disease Diseases 0.000 description 2
• 208000035032 Multiple sulfatase deficiency Diseases 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 102100031688 N-acetylgalactosamine-6-sulfatase Human genes 0.000 description 2
• CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
• 208000014060 Niemann-Pick disease Diseases 0.000 description 2
• 201000000788 Niemann-Pick disease type C1 Diseases 0.000 description 2
• 108091028043 Nucleic acid sequence Proteins 0.000 description 2
• 108010033276 Peptide Fragments Proteins 0.000 description 2
• 102000007079 Peptide Fragments Human genes 0.000 description 2
• 241000700157 Rattus norvegicus Species 0.000 description 2
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 208000013608 Salla disease Diseases 0.000 description 2
• 208000021811 Sandhoff disease Diseases 0.000 description 2
• 208000000828 Sialic Acid Storage Disease Diseases 0.000 description 2
• 208000017460 Sialidosis type 2 Diseases 0.000 description 2
• 201000001828 Sly syndrome Diseases 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• 208000022292 Tay-Sachs disease Diseases 0.000 description 2
• 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 description 2
• 101710132062 Transitional endoplasmic reticulum ATPase Proteins 0.000 description 2
• 108700001567 Type I Schindler Disease Proteins 0.000 description 2
• 208000026589 Wolman disease Diseases 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 210000001642 activated microglia Anatomy 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 230000003044 adaptive effect Effects 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
• 210000004727 amygdala Anatomy 0.000 description 2
• 210000000702 aorta abdominal Anatomy 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 210000003050 axon Anatomy 0.000 description 2
• 230000004888 barrier function Effects 0.000 description 2
• 238000002869 basic local alignment search tool Methods 0.000 description 2
• 230000003115 biocidal effect Effects 0.000 description 2
• 238000003766 bioinformatics method Methods 0.000 description 2
• 239000005388 borosilicate glass Substances 0.000 description 2
• 239000008366 buffered solution Substances 0.000 description 2
• 239000007978 cacodylate buffer Substances 0.000 description 2
• 238000005251 capillar electrophoresis Methods 0.000 description 2
• 210000000845 cartilage Anatomy 0.000 description 2
• 238000005277 cation exchange chromatography Methods 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 229940106189 ceramide Drugs 0.000 description 2
• ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
• 229930183167 cerebroside Natural products 0.000 description 2
• RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
• 208000024042 cholesterol ester storage disease Diseases 0.000 description 2
• 208000013760 cholesteryl ester storage disease Diseases 0.000 description 2
• 230000008045 co-localization Effects 0.000 description 2
• 230000003930 cognitive ability Effects 0.000 description 2
• 238000004891 communication Methods 0.000 description 2
• 230000006854 communication Effects 0.000 description 2
• 150000001875 compounds Chemical class 0.000 description 2
• 238000004590 computer program Methods 0.000 description 2
• 239000000356 contaminant Substances 0.000 description 2
• 230000037029 cross reaction Effects 0.000 description 2
• 210000000805 cytoplasm Anatomy 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 230000007850 degeneration Effects 0.000 description 2
• 238000002716 delivery method Methods 0.000 description 2
• 210000001787 dendrite Anatomy 0.000 description 2
• 230000008021 deposition Effects 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 238000010586 diagram Methods 0.000 description 2
• 238000010494 dissociation reaction Methods 0.000 description 2
• 230000005593 dissociations Effects 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 210000001951 dura mater Anatomy 0.000 description 2
• 210000003038 endothelium Anatomy 0.000 description 2
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
• 238000013401 experimental design Methods 0.000 description 2
• 210000003608 fece Anatomy 0.000 description 2
• 210000003754 fetus Anatomy 0.000 description 2
• 239000000835 fiber Substances 0.000 description 2
• 229940012952 fibrinogen Drugs 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 239000013022 formulation composition Substances 0.000 description 2
• 201000008049 fucosidosis Diseases 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 238000001415 gene therapy Methods 0.000 description 2
• 208000016361 genetic disease Diseases 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 210000001905 globus pallidus Anatomy 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
• 230000010370 hearing loss Effects 0.000 description 2
• 231100000888 hearing loss Toxicity 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• 208000003906 hydrocephalus Diseases 0.000 description 2
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
• 229940050526 hydroxyethylstarch Drugs 0.000 description 2
• 208000013403 hyperactivity Diseases 0.000 description 2
• 239000000819 hypertonic solution Substances 0.000 description 2
• 229940021223 hypertonic solution Drugs 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• 230000002427 irreversible effect Effects 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 238000009593 lumbar puncture Methods 0.000 description 2
• 210000005230 lumbar spinal cord Anatomy 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
• 210000002891 metencephalon Anatomy 0.000 description 2
• 230000007388 microgliosis Effects 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 238000001565 modulated differential scanning calorimetry Methods 0.000 description 2
• 230000004001 molecular interaction Effects 0.000 description 2
• 208000020468 mucolipidosis III alpha/beta Diseases 0.000 description 2
• 208000000690 mucopolysaccharidosis VI Diseases 0.000 description 2
• 208000020004 mucopolysaccharidosis type 9 Diseases 0.000 description 2
• 208000012091 mucopolysaccharidosis type IVB Diseases 0.000 description 2
• 238000000569 multi-angle light scattering Methods 0.000 description 2
• 210000003007 myelin sheath Anatomy 0.000 description 2
• 230000023105 myelination Effects 0.000 description 2
• 210000004237 neck muscle Anatomy 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 description 2
• 201000007642 neuronal ceroid lipofuscinosis 1 Diseases 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
• 210000000869 occipital lobe Anatomy 0.000 description 2
• 210000002589 oculomotor nerve Anatomy 0.000 description 2
• 210000000956 olfactory bulb Anatomy 0.000 description 2
• 210000001328 optic nerve Anatomy 0.000 description 2
• 210000005112 optic tract Anatomy 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 210000001428 peripheral nervous system Anatomy 0.000 description 2
• 229920001296 polysiloxane Polymers 0.000 description 2
• 229920000136 polysorbate Polymers 0.000 description 2
• 229940068965 polysorbates Drugs 0.000 description 2
• 230000006920 protein precipitation Effects 0.000 description 2
• 201000010108 pycnodysostosis Diseases 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 238000010188 recombinant method Methods 0.000 description 2
• 210000000463 red nucleus Anatomy 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 238000004007 reversed phase HPLC Methods 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 238000005070 sampling Methods 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 230000035939 shock Effects 0.000 description 2
• 208000011985 sialidosis Diseases 0.000 description 2
• 210000002027 skeletal muscle Anatomy 0.000 description 2
• 208000019116 sleep disease Diseases 0.000 description 2
• 208000022925 sleep disturbance Diseases 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 235000010356 sorbitol Nutrition 0.000 description 2
• 230000000087 stabilizing effect Effects 0.000 description 2
• 239000008223 sterile water Substances 0.000 description 2
• 239000011232 storage material Substances 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 210000000495 subthalamus Anatomy 0.000 description 2
• 230000008961 swelling Effects 0.000 description 2
• 238000010189 synthetic method Methods 0.000 description 2
• 230000002123 temporal effect Effects 0.000 description 2
• 210000001550 testis Anatomy 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 2
• 210000003462 vein Anatomy 0.000 description 2
• 210000004785 virchow-robin space Anatomy 0.000 description 2
• 210000001835 viscera Anatomy 0.000 description 2
• BFCDFTHTSVTWOG-PXNSSMCTSA-N (1r,2s)-2-(octylamino)-1-(4-propan-2-ylsulfanylphenyl)propan-1-ol Chemical compound CCCCCCCCN[C@@H](C)[C@H](O)C1=CC=C(SC(C)C)C=C1 BFCDFTHTSVTWOG-PXNSSMCTSA-N 0.000 description 1
• PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
• LMVGXBRDRZOPHA-UHFFFAOYSA-N 2-[dimethyl-[3-(16-methylheptadecanoylamino)propyl]azaniumyl]acetate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O LMVGXBRDRZOPHA-UHFFFAOYSA-N 0.000 description 1
• TYIOVYZMKITKRO-UHFFFAOYSA-N 2-[hexadecyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O TYIOVYZMKITKRO-UHFFFAOYSA-N 0.000 description 1
• SNQVCAOGQHOSEN-UHFFFAOYSA-N 2-[methyl(octadecyl)amino]acetic acid Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC(O)=O SNQVCAOGQHOSEN-UHFFFAOYSA-N 0.000 description 1
• FZLJPEPAYPUMMR-RTRLPJTCSA-N 2-acetamido-2-deoxy-D-glucopyranose 1-phosphate Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OP(O)(O)=O FZLJPEPAYPUMMR-RTRLPJTCSA-N 0.000 description 1
• DIROHOMJLWMERM-UHFFFAOYSA-N 3-[dimethyl(octadecyl)azaniumyl]propane-1-sulfonate Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O DIROHOMJLWMERM-UHFFFAOYSA-N 0.000 description 1
• 229930195730 Aflatoxin Natural products 0.000 description 1
• XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
• 239000012103 Alexa Fluor 488 Substances 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• 101150007653 Arsa gene Proteins 0.000 description 1
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 238000011725 BALB/c mouse Methods 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 208000031638 Body Weight Diseases 0.000 description 1
• 208000024806 Brain atrophy Diseases 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 238000011740 C57BL/6 mouse Methods 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 206010008096 Cerebral atrophy Diseases 0.000 description 1
• 241000282552 Chlorocebus aethiops Species 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 101100121089 Danio rerio galc gene Proteins 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
• 241000045500 Diseae Species 0.000 description 1
• 241001269524 Dura Species 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 239000004386 Erythritol Substances 0.000 description 1
• UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
• 108010008165 Etanercept Proteins 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 201000011240 Frontotemporal dementia Diseases 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 229930186217 Glycolipid Natural products 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
• 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 108700012441 IGF2 Proteins 0.000 description 1
• 108010003381 Iduronidase Proteins 0.000 description 1
• 102000004627 Iduronidase Human genes 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
• 206010022773 Intracranial pressure increased Diseases 0.000 description 1
• 206010022998 Irritability Diseases 0.000 description 1
• DYDCUQKUCUHJBH-REOHCLBHSA-N L-Cycloserine Chemical compound N[C@H]1CONC1=O DYDCUQKUCUHJBH-REOHCLBHSA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 101150048357 Lamp1 gene Proteins 0.000 description 1
• 244000147568 Laurus nobilis Species 0.000 description 1
• 235000017858 Laurus nobilis Nutrition 0.000 description 1
• 241000282560 Macaca mulatta Species 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 208000007650 Meningeal Carcinomatosis Diseases 0.000 description 1
• 208000027382 Mental deterioration Diseases 0.000 description 1
• 206010027374 Mental impairment Diseases 0.000 description 1
• 206010051696 Metastases to meninges Diseases 0.000 description 1
• 206010061296 Motor dysfunction Diseases 0.000 description 1
• 206010072928 Mucolipidosis type II Diseases 0.000 description 1
• 206010072930 Mucolipidosis type IV Diseases 0.000 description 1
• 102100026502 Mucolipin-1 Human genes 0.000 description 1
• 101000822667 Mus musculus Something about silencing protein 10 Proteins 0.000 description 1
• 208000008238 Muscle Spasticity Diseases 0.000 description 1
• 108010006140 N-sulfoglucosamine sulfohydrolase Proteins 0.000 description 1
• 201000000785 Niemann-Pick disease type C2 Diseases 0.000 description 1
• 238000010222 PCR analysis Methods 0.000 description 1
• 238000012879 PET imaging Methods 0.000 description 1
• 239000002033 PVDF binder Substances 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
• 208000024571 Pick disease Diseases 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 229920000153 Povidone-iodine Polymers 0.000 description 1
• GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
• 108010094028 Prothrombin Proteins 0.000 description 1
• 102100027378 Prothrombin Human genes 0.000 description 1
• MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
• 241000219061 Rheum Species 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 208000025804 Sanfilippo syndrome type D Diseases 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
• 108010000499 Thromboplastin Proteins 0.000 description 1
• 102000002262 Thromboplastin Human genes 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
• 244000000188 Vaccinium ovalifolium Species 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 206010072731 White matter lesion Diseases 0.000 description 1
• 238000002441 X-ray diffraction Methods 0.000 description 1
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
• 239000002251 absorbable suture material Substances 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 239000005409 aflatoxin Substances 0.000 description 1
• 239000003732 agents acting on the eye Substances 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 230000036626 alertness Effects 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 201000008333 alpha-mannosidosis Diseases 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 210000003484 anatomy Anatomy 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 230000003140 astrocytic effect Effects 0.000 description 1
• 230000008335 axon cargo transport Effects 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• BVGLIYRKPOITBQ-ANPZCEIESA-N benzylpenicillin benzathine Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 BVGLIYRKPOITBQ-ANPZCEIESA-N 0.000 description 1
• WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 description 1
• 201000006486 beta-mannosidosis Diseases 0.000 description 1
• 229940064804 betadine Drugs 0.000 description 1
• 229960003237 betaine Drugs 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 239000010796 biological waste Substances 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
• 239000012496 blank sample Substances 0.000 description 1
• 230000005821 brain abnormality Effects 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 230000003139 buffering effect Effects 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 239000003560 cancer drug Substances 0.000 description 1
• IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
• 229960003184 carprofen Drugs 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000030570 cellular localization Effects 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
• 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
• 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
• 238000002983 circular dichroism Methods 0.000 description 1
• 230000006999 cognitive decline Effects 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 238000004624 confocal microscopy Methods 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• 229960002806 daclizumab Drugs 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 231100000895 deafness Toxicity 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 231100000517 death Toxicity 0.000 description 1
• 239000008367 deionised water Substances 0.000 description 1
• 229910021641 deionized water Inorganic materials 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 230000000378 dietary effect Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 229910001882 dioxygen Inorganic materials 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 238000011833 dog model Methods 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 230000005670 electromagnetic radiation Effects 0.000 description 1
• 238000000635 electron micrograph Methods 0.000 description 1
• 238000001493 electron microscopy Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000002327 eosinophilic effect Effects 0.000 description 1
• 230000001667 episodic effect Effects 0.000 description 1
• 210000000647 epithalamus Anatomy 0.000 description 1
• UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
• 229940009714 erythritol Drugs 0.000 description 1
• 235000019414 erythritol Nutrition 0.000 description 1
• 229960000403 etanercept Drugs 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 230000022244 formylation Effects 0.000 description 1
• 238000006170 formylation reaction Methods 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 210000000609 ganglia Anatomy 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 230000009477 glass transition Effects 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 239000003292 glue Substances 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 210000002288 golgi apparatus Anatomy 0.000 description 1
• 238000005469 granulation Methods 0.000 description 1
• 230000003179 granulation Effects 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 229910001385 heavy metal Inorganic materials 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 230000036732 histological change Effects 0.000 description 1
• 238000013427 histology analysis Methods 0.000 description 1
• 102000044162 human IGF1 Human genes 0.000 description 1
• 150000002433 hydrophilic molecules Chemical class 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 210000003405 ileum Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 238000003125 immunofluorescent labeling Methods 0.000 description 1
• 238000002650 immunosuppressive therapy Methods 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 208000016245 inborn errors of metabolism Diseases 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 210000003140 lateral ventricle Anatomy 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 208000036546 leukodystrophy Diseases 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 238000005567 liquid scintillation counting Methods 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 238000012153 long-term therapy Methods 0.000 description 1
• 230000001050 lubricating effect Effects 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 230000002535 lyotropic effect Effects 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• 230000031852 maintenance of location in cell Effects 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 150000002704 mannoses Chemical class 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 210000000274 microglia Anatomy 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
• 239000004223 monosodium glutamate Substances 0.000 description 1
• 235000013923 monosodium glutamate Nutrition 0.000 description 1
• 230000004660 morphological change Effects 0.000 description 1
• 230000001095 motoneuron effect Effects 0.000 description 1
• 239000012120 mounting media Substances 0.000 description 1
• 208000020460 mucolipidosis II alpha/beta Diseases 0.000 description 1
• 208000005340 mucopolysaccharidosis III Diseases 0.000 description 1
• 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 description 1
• 208000036725 mucopolysaccharidosis type 3D Diseases 0.000 description 1
• 208000027333 mucopolysaccharidosis type IIID Diseases 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• NZXVYLJKFYSEPO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-16-methylheptadecanamide Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)NCCCN(C)C NZXVYLJKFYSEPO-UHFFFAOYSA-N 0.000 description 1
• 210000000478 neocortex Anatomy 0.000 description 1
• 238000004848 nephelometry Methods 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 210000005044 neurofilament Anatomy 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000003982 neuronal uptake Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 230000003448 neutrophilic effect Effects 0.000 description 1
• 231100000989 no adverse effect Toxicity 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 230000035764 nutrition Effects 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 238000006384 oligomerization reaction Methods 0.000 description 1
• 229940125702 ophthalmic agent Drugs 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 239000012285 osmium tetroxide Substances 0.000 description 1
• 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
• 235000019371 penicillin G benzathine Nutrition 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 230000003836 peripheral circulation Effects 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000000088 plastic resin Substances 0.000 description 1
• 229920001993 poloxamer 188 Polymers 0.000 description 1
• 229940044519 poloxamer 188 Drugs 0.000 description 1
• 239000004417 polycarbonate Substances 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 150000003071 polychlorinated biphenyls Chemical class 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
• 210000002975 pon Anatomy 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 229960001621 povidone-iodine Drugs 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 229940071643 prefilled syringe Drugs 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 238000002360 preparation method Methods 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 229940039716 prothrombin Drugs 0.000 description 1
• 230000010349 pulsation Effects 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 230000005258 radioactive decay Effects 0.000 description 1
• MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 238000001223 reverse osmosis Methods 0.000 description 1
• 238000009738 saturating Methods 0.000 description 1
• 210000004761 scalp Anatomy 0.000 description 1
• 210000004116 schwann cell Anatomy 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 210000000717 sertoli cell Anatomy 0.000 description 1
• 239000004447 silicone coating Substances 0.000 description 1
• 239000002356 single layer Substances 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• 230000007958 sleep Effects 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 239000012064 sodium phosphate buffer Substances 0.000 description 1
• HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 208000018198 spasticity Diseases 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 150000003408 sphingolipids Chemical class 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 238000012453 sprague-dawley rat model Methods 0.000 description 1
• 229910001220 stainless steel Inorganic materials 0.000 description 1
• 239000010935 stainless steel Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 238000013517 stratification Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 150000005846 sugar alcohols Chemical class 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 238000004114 suspension culture Methods 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 238000012385 systemic delivery Methods 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 239000008399 tap water Substances 0.000 description 1
• 235000020679 tap water Nutrition 0.000 description 1
• 229940104261 taurate Drugs 0.000 description 1
• 210000004062 tegmentum mesencephali Anatomy 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 229950004616 tribromoethanol Drugs 0.000 description 1
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
• 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 238000003260 vortexing Methods 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 239000000811 xylitol Substances 0.000 description 1
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
• 235000010447 xylitol Nutrition 0.000 description 1
• 229960002675 xylitol Drugs 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1